Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Up 35.4% in December

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 122,300 shares, an increase of 35.4% from the December 15th total of 90,300 shares. Based on an average daily volume of 169,400 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.3% of the company’s stock are short sold.

Hedge Funds Weigh In On Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. BML Capital Management LLC increased its holdings in Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,100,002 shares of the company’s stock after acquiring an additional 3,474,828 shares during the quarter. Achilles Therapeutics comprises about 2.5% of BML Capital Management LLC’s investment portfolio, making the stock its 11th biggest holding. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Stock Down 0.9 %

NASDAQ ACHL opened at $1.16 on Thursday. The firm has a market capitalization of $47.68 million, a PE ratio of -0.70 and a beta of 1.32. The stock’s 50 day moving average is $1.08 and its 200 day moving average is $0.93. Achilles Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.76.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.